- Home
- BCAB vs NCNA Comparison
BCAB vs NCNA Comparison
Compare BCAB & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | NCNA |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.7M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BCAB | NCNA |
|---|---|---|
| Price | $4.07 | $1.41 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 56.3K | 47.2K |
| Earning Date | 05-08-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.03 |
| 52 Week High | $6.52 | $10.00 |
Technical Indicators
Market Signals| Indicator | BCAB | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 28.23 |
| Support Level | $3.92 | $1.33 |
| Resistance Level | $4.22 | $2.27 |
| Average True Range (ATR) | 0.38 | 0.15 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 49.64 | 3.33 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.